These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2081686)

  • 1. 24-month follow-up of multiple sclerosis patients treated with cyclophosphamide.
    Millefiorini E; Di Giovanni M; Bernardi S; Grasso MG; Di Giampietro A; Gambi D
    Ital J Neurol Sci; 1990 Dec; 11(6):605-7. PubMed ID: 2081686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis.
    Siracusa GF; Amato MP; Fratiglioni L; Sità D; Amaducci L
    Ital J Neurol Sci; 1987 Dec; 8(6):589-92. PubMed ID: 3429217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide in relapsing remitting multiple sclerosis.
    D'Andrea F; D'Aurizio C; Marini C; Prencipe M
    Ital J Neurol Sci; 1990 Jun; 11(3):271-4. PubMed ID: 2387697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
    Weiner HL; Mackin GA; Orav EJ; Hafler DA; Dawson DM; LaPierre Y; Herndon R; Lehrich JR; Hauser SL; Turel A
    Neurology; 1993 May; 43(5):910-8. PubMed ID: 8388090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
    Patti F; Reggio E; Palermo F; Fiorilla T; Politi G; Nicoletti A; Reggio A
    J Neurol; 2004 Dec; 251(12):1502-6. PubMed ID: 15645351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the results of treating progressive multiple sclerosis with cyclophosphamide].
    Wajgt A; Szyrocka-Szwed K; Gadomska B; Szczechowski L
    Neurol Neurochir Pol; 1988; 22(6):518-23. PubMed ID: 3077433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lymphocytapheresis plus cyclophosphamide on the course of a chronic progressive form of multiple sclerosis.
    Ferla S; Meneghetti G; Spartà S; Belloni M; Ongaro G
    Ital J Neurol Sci; 1985 Sep; 6(3):283-6. PubMed ID: 4066266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
    Hommes OR; Prick JJ; Lamers KJ
    Clin Neurol Neurosurg; 1975; 78(1):59-72. PubMed ID: 1157430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of multiple sclerosis with intravenous hydrocortisone hemisuccinate in combination with cyclophosphamide or cytosine arabinoside].
    Cendrowski W
    Neurol Neurochir Pol; 1974; 8(1):47-52. PubMed ID: 4407711
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects.
    Mauch E; Kornhuber HH; Pfrommer U; Hähnel A; Laufen H; Krapf H
    Eur Arch Psychiatry Neurol Sci; 1989; 238(3):115-7. PubMed ID: 2721530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-laboratory study of methylprednisolone and cyclophosphamide treatment in patients with multiple sclerosis relapse.
    Manova MG; Kostadinova II; Rangelov AA
    Folia Med (Plovdiv); 2000; 42(3):20-5. PubMed ID: 11347331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study.
    Theys P; Gosseye-Lissoir F; Ketelaer P; Carton H
    J Neurol; 1981; 225(2):119-33. PubMed ID: 6164763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy.
    Goodkin DE; Plencner S; Palmer-Saxerud J; Teetzen M; Hertsgaard D
    Arch Neurol; 1987 Aug; 44(8):823-7. PubMed ID: 2820359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide therapy for MS.
    Gauthier SA; Weiner HL
    Int MS J; 2005 Aug; 12(2):52-8. PubMed ID: 16417815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
    Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
    J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
    Rinaldi L; Perini P; Calabrese M; Gallo P
    Neurol Sci; 2009 Oct; 30 Suppl 2():S171-3. PubMed ID: 19882369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.